| Schedule of significant expense categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
June 30, |
|
June 30, |
|
2026 |
|
2025 |
|
2026 |
|
2025 |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Clinical |
$ |
2,301,995 |
|
$ |
1,630,084 |
|
$ |
4,111,415 |
|
$ |
3,447,316 |
Chemical, manufacturing and controls |
|
505,131 |
|
|
558,916 |
|
|
770,856 |
|
|
694,038 |
Research and preclinical |
|
731 |
|
|
8,094 |
|
|
(4,903) |
|
|
32,228 |
Regulatory |
|
4,663 |
|
|
5,628 |
|
|
19,325 |
|
|
27,286 |
Other research and development costs |
|
433,999 |
|
|
367,221 |
|
|
1,019,605 |
|
|
806,073 |
Total research and development |
|
3,246,519 |
|
|
2,569,943 |
|
|
5,916,298 |
|
|
5,006,941 |
General and administrative expenses |
|
1,626,109 |
|
|
1,353,172 |
|
|
4,032,696 |
|
|
3,346,100 |
IPR&D impairment |
|
9,190,897 |
|
|
— |
|
|
9,190,897 |
|
|
— |
Total operating expenses |
$ |
14,063,525 |
|
$ |
3,923,115 |
|
$ |
19,139,891 |
|
$ |
8,353,041 |
Sublease income |
|
(17,442) |
|
|
— |
|
|
(36,897) |
|
|
— |
Loss on debt conversion with related party |
|
— |
|
|
— |
|
|
— |
|
|
6,134,120 |
Interest (income)/expense, net |
|
(66,349) |
|
|
(111,379) |
|
|
(143,699) |
|
|
35,711 |
Exchange loss, net |
|
30,569 |
|
|
(4,532) |
|
|
36,429 |
|
|
18,742 |
Net loss before income taxes |
$ |
14,010,303 |
|
$ |
3,807,204 |
|
$ |
18,995,724 |
|
$ |
14,541,614 |
|